Bioactive glass-polymer composite bone scaffolds
Disclosed herein is a technology for healing bone defects using bioactive silicate glass (BSG) and a 3D osteomimetic composite porous scaffold containing microspheres comprised of poly(lactide-co-glycolide) (PLGA).
1. A composite scaffold material of microspheres comprising a biodegradable polymer and a bioactive silicate glass (BSG), wherein said BSG comprises SiO 2 , P 2 O 5 , and CaO, and Na 2 O is absent in said BSG, and wherein said BSG is dispersed in said biodegradable polymer to form a microsphere with a diameter from 250 μm to 500 μm, and wherein pores of said porous biocompatible scaffold material account for about 20-40% of the scaffold total volume with sufficient pore sizes of at least 100 μm to allow for seeding and growth of cells.
2. The composite scaffold material of microspheres according to claim 1 , wherein the biodegradable polymer comprises poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), poly(propylene fumarate), collagen, polyphosphazenes, polyanhydrides, poly(amino acids), polyhydroxyalkanoates, polyethylene glycol (PEG), polydioxanone (PDO), a polysaccharide, or a combination of two or more said biodegradable polymers.
3. The composite scaffold material of microspheres according to claim 1 , wherein the BSG accounts for 2%-30% by weight of the composite.
4. The composite scaffold material of microspheres according to claim 3 , wherein the BSG comprises about 9% by weight of the composite.
5. The composite scaffold material of microspheres according to claim 1 , wherein the BSG comprises about 6˜80 mol % SiO 2 .
6. The composite scaffold material of microspheres according to claim 1 , wherein the BSG comprises about 0˜70 mol % P 2 O 5 .
7. The composite scaffold material of microspheres according to claim 1 , wherein the BSG comprises about 15˜85 mol % CaO.
8. The composite scaffold material of microspheres according to claim 1 , wherein the BSG comprises about 10.8 mol % P 2 O 5 , about 54.2 mol % SiO 2 , and about 35.0 mol % CaO.
9. The composite scaffold material of claim 1 , wherein the scaffold material has mechanical properties compatible with native bone with a compressive modulus value in the range of 300-600 MPa.
10. A method of fabricating a composite scaffold material of claim 1 , comprising the steps of:
a. dissolving a biodegradable polymer selected from the group consisting of poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), poly(propylene fumarate), collagen, polyphosphazenes, polyanhydrides, poly(amino acids), polyhydroxyalkanoates, polyethylene glycol (PEG), polydioxanone (PDO), a polysaccharide, or a combination of any two or more said biodegradable polymers in a solvent to form a polymer solution;
b. adding BSG powder, wherein said BSG powder comprises SiO 2 , P 2 O 5 , and CaO, and Na 2 O is absent in said BSG, into the polymer solution to afford a polymer/glass suspension solution; and
c. pouring the polymer/glass suspension solution into a polyvinyl alcohol (PVA) solution to afford a mixture and removing the solvent from the mixture under stirring followed by drying and sintering temperature to afford the composite scaffold material of microspheres.
11. The method of claim 10 , wherein the BSG powder is incorporated said polymer/glass suspension solution via sonication, vortex mixing, or a combination thereof.
12. The method of claim 10 , wherein the solvent is an organic or an inorganic compatible solvent.
13. A method of effecting bone repair comprising contacting an area affected by a bone defect with the composite scaffold material of claim 1 .
14. The method of claim 13 , wherein the composite scaffold material further comprises a bioactive agent selected from the group consisting of bone morphogenic proteins (BMPs), vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), osteoprotegerin, growth differentiation factors (GDFs), cartilage-derived morphogenic proteins (CDMPs), LIM mineralization proteins (LMPs), transforming growth factor β (TGFβ), antibiotics, immunosuppressive agents, and any combinations thereof.
15. The method of claim 13 , wherein the composite scaffold material further contains host-derived cells comprising mesenchymal stem cells, osteoprogenitors, pre-osteoblasts, osteoblasts, or a combination thereof.